Evidence map›Paper›PMID 32092857›Full record

ArticleViruses2020

Novel Lentivirus-Based Method for Rapid Selection of Inhibitory Nanobody against PRRSV.

Ze-Hui Liu, Kai-Xia Lei, Guang-Wei Han, Hui-Ling Xu, Fang He

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Exploring cellular biochemistry with nanobodies.The Journal of biological chemistry · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ze-Hui LiuInstitute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, Hangzhou 310058, China.
Kai-Xia LeiInstitute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, Hangzhou 310058, China.
Guang-Wei HanInstitute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, Hangzhou 310058, China.
Hui-Ling XuInstitute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, Hangzhou 310058, China.
Fang HeInstitute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, Hangzhou 310058, China.
Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence and re-emergence of porcine reproductive and respiratory syndrome virus (PRRSV) has resulted in huge economic losses for the swine industry. Current vaccines are of limited efficacy against endemic circulating PRRSV variants. New strategies against PRRSV infection are in urgent need. Here, a nanobody library in Marc-145 cells is constructed for antiviral nanobodies. Nanobody encoding sequences from two non-immunized llamas were cloned to generate a pseudotyped lentiviral library. Several candidates were selected from survival cells post-PRRSV inoculation and further characterized. Nb9 was identified with strong antiviral activity. Moreover, Nb9 exerted antiviral activity via its interaction with PRRSV viral proteins, as revealed by immunofluorescence assay and Western blot. Taken together, the novel function-based screen of the lentivirus nanobody library, instead of the conventional affinity-based screen, offers an alternative strategy for antiviral reagents against PRRSV and other pathogens.

Indexed as

AnimalsAntiviral AgentsCamelids, New WorldCell LineLentivirusPeptide LibraryPorcine respiratory and reproductive syndrome virusSingle-Domain AntibodiesSwineVirus ReplicationAntiviral AgentsPeptide LibrarySingle-Domain Antibodiesantiviral strategylentivirus based nanobody librarynanobody selectionPRRSV

Identifiers

PMID32092857
PMCPMC7077216
OpenAlexW3007696245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.